Laikai Pharmaceutical-B announced that the Group has successfully completed a phase I single-dose escalation study of LAE103 in overweight or obese subjects in Australia. The SAD study was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic properties of LAE103 in overweight or obese subjects.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.